B7‐33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction–Related Adverse Cardiac Remodeling in MiceTeja Devarakonda, Fadi N. Salloum|Journal of the American Heart Association|2020Cited by 20
Chronic treatment with serelaxin mitigates adverse remodeling in a murine model of ischemic heart failure and modulates bioactive sphingolipid signalingTeja Devarakonda, Fadi N. Salloum|Scientific Reports|2022Cited by 8